0001104659-19-032915.txt : 20190530 0001104659-19-032915.hdr.sgml : 20190530 20190530212610 ACCESSION NUMBER: 0001104659-19-032915 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190528 FILED AS OF DATE: 20190530 DATE AS OF CHANGE: 20190530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BINGHAM KATE CENTRAL INDEX KEY: 0001185040 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 19868372 MAIL ADDRESS: STREET 1: 1365 MAIN STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4 1 a4.xml 4 X0306 4 2019-05-28 0 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001185040 BINGHAM KATE C/O BICYCLE THERAPEUTICS PLC B900, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT UNITED KINGDOM 1 0 0 0 Ordinary Shares 2019-05-28 4 C 0 874709 A 874709 I By SV Life Sciences Fund V, L.P. Ordinary Shares 2019-05-28 4 C 0 623196 A 1497905 I By SV Life Sciences Fund V, L.P. Ordinary Shares 2019-05-28 4 C 0 18485 A 18485 I By SV Life Sciences Fund V Strategic Partners. L.P. Ordinary Shares 2019-05-28 4 C 0 13169 A 31654 I By SV Life Sciences Fund V Strategic Partners. L.P. Ordinary Shares 2019-05-28 4 P 0 377732 14 A 1875637 I By SV Life Sciences Fund V, L.P. Ordinary Shares 2019-05-28 4 P 0 7983 14 A 39637 I By SV Life Sciences Fund V Strategic Partners. L.P. Series A Preferred Shares 2019-05-28 4 C 0 874709 D Ordinary Shares 874709 0 I By SV Life Sciences Fund V, L.P. Series B1 Preferred Shares 2019-05-28 4 C 0 623196 D Ordinary Shares 623196 0 I By SV Life Sciences Fund V, L.P. Series A Preferred Shares 2019-05-28 4 C 0 18485 D Ordinary Shares 18485 0 I By SV Life Sciences Fund V Strategic Partners. L.P. Series B1 Preferred Shares 2019-05-28 4 C 0 13169 D Ordinary Shares 13169 0 I By SV Life Sciences Fund V Strategic Partners. L.P. Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein /s/ Lee Kalowski, as Attorney-in-Fact 2019-05-30